Kalaris Therapeutics (NASDAQ:KLRS) Research Coverage Started at Chardan Capital

Chardan Capital began coverage on shares of Kalaris Therapeutics (NASDAQ:KLRS) in a research note issued to investors on Tuesday, Marketbeat reports. The firm issued a buy rating and a $19.00 price objective on the stock.

KLRS has been the topic of several other research reports. Wall Street Zen upgraded shares of Kalaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 20th. Citigroup reissued an “outperform” rating on shares of Kalaris Therapeutics in a report on Thursday, December 18th. Citizens Jmp initiated coverage on shares of Kalaris Therapeutics in a research note on Monday, November 3rd. They set a “market outperform” rating and a $20.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kalaris Therapeutics in a report on Monday. Finally, Raymond James Financial started coverage on shares of Kalaris Therapeutics in a research note on Tuesday, September 2nd. They issued a “strong-buy” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $14.00.

Kalaris Therapeutics Trading Down 0.8%

KLRS stock opened at $9.58 on Tuesday. Kalaris Therapeutics has a 1-year low of $2.14 and a 1-year high of $12.90. The business’s 50 day moving average is $6.38 and its 200-day moving average is $4.52. The firm has a market cap of $179.15 million, a P/E ratio of -2.54 and a beta of -0.04.

Kalaris Therapeutics (NASDAQ:KLRS) last posted its earnings results on Wednesday, November 12th. The company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.66) by $0.02.

Institutional Trading of Kalaris Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of KLRS. Woodline Partners LP acquired a new stake in Kalaris Therapeutics in the third quarter worth $1,394,000. Bridgeway Capital Management LLC bought a new position in Kalaris Therapeutics during the third quarter worth about $130,000. XTX Topco Ltd acquired a new position in Kalaris Therapeutics in the second quarter valued at about $65,000. Johnson Financial Group Inc. bought a new stake in shares of Kalaris Therapeutics in the third quarter worth about $58,000. Finally, Belpointe Asset Management LLC acquired a new stake in shares of Kalaris Therapeutics during the third quarter worth about $231,000. 66.05% of the stock is owned by institutional investors.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.